| 标题 |
Glofitamab Plus Polatuzumab Vedotin Continues to Demonstrate Frequent and Durable Responses and Has a Manageable Safety Profile in Patients with ≥2L Relapsed/Refractory DLBCL, Including HGBCL, and in Patients with Prior CAR T-Cell Therapy: Updated Results from a Phase Ib/II Study
在≥2 L复发/难治性DLBCL（包括HGBCL）患者和既往接受过CAR T细胞治疗的患者中，Glofitamab联合Polatuzumab Vedotin继续表现出频繁和持久的缓解，并且具有可管理的安全性特征：来自Ib/II期研究的更新结果
|
| 网址 |
求助人暂未提供
|
| DOI |
暂未提供，该求助的时间将会延长，查看原因？
|
| 其它 | Blood. 2023;142(Supplement 1):4460-4460. |
| 求助人 | |
| 下载 |
毛豆
Yifan2024
ceeray23
cocolu
SYLH
藤椒辣鱼
bruna
Chillichee
杳鸢
shinysparrow
从容的无极
Holy
IlIIlIlIIIllI
IIIIIllllIIII
xiaxiao
33
MchemG
剑指东方是为谁
无名老大
tursun
皖公网安备34019202002308
